• 1
    Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004; 6: 109-118.
  • 2
    Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer—the present. Histopathology. 2008; 52: 82-90.
  • 3
    Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005; 103: 2241-2251.
  • 4
    Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
  • 5
    Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 1451-1467.
  • 6
    Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998; 51: 227-238.
  • 7
    NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2009. Fort Washington, PA: National Comprehensive Cancer Network; 2009.
  • 8
    Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet. 2009; 373: 1463-1479.
  • 9
    Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008; 21 (suppl 2): S8-S15.
  • 10
    Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009; 27: 5700-5706.
  • 11
    Albert JM, Gonzalez-Angulo AM, Guray M, et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010; 77: 1296-1302.
  • 12
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 547-581.
  • 13
    Cox DR, Oakes N. Analysis of survival data. New York, NY: Chapman and Hall; 1988.
  • 14
    Woodward WA, Strom EA, Tucker SL, et al. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003; 57: 336-344.
  • 15
    Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of 1 centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001; 93: 112-120.
  • 16
    Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992; 10: 1284-1291.
  • 17
    Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in 2 large breast cancer databases. J Clin Oncol. 2003; 21: 1973-1979.
  • 18
    Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28: 2784-2795.